By Chris Wack
Trevi Therapeutics shares were up 72% at $4.27 after the company said it saw had a positive outcome from the planned sample size re-estimation for its ongoing Phase 2b trial in idiopathic pulmonary fibrosis patients with chronic cough.
Shares in the New Haven, Conn., company hit their 52-week high of $4.50 earlier in the session, and are up 222% in the past 12 months.
The clinical-stage biopharmaceutical company said it doesn't require any changes to the current sample size for the trial.
The trial has reached 75% of the targeted enrollment, and topline results from the full trial continue to be expected in the first half of 2025.
The analysis was conducted on the highest dose in the trial after 50% of the initial targeted trial enrollment, or 80 patients, completed the six weeks of treatment. Based on the analysis, it was recommended that the trial should continue as planned to maintain the pre-specified conditional power of 80% or greater.
The primary efficacy endpoint for the trial is the relative change in 24-hour cough frequency at the end of week six versus baseline. The trial will also explore secondary endpoints, including patient reported outcome measures for cough.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 12, 2024 10:17 ET (15:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。